A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
ASCO 2023 – Morpheus spurs Roche to take the red pill
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.
